Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by AIM ImmunoTech Inc.

< Previous 1 2 3 4 Next >
AIM ImmunoTech Announces European Patent Office Grants Patent Covering Ampligen® (Rintatolimod) for Use in the Treatment of the Post-COVID Condition of Fatigue
From AIM ImmunoTech Inc.
Via GlobeNewswire
AIM ImmunoTech to Attend the 2025 Maxim Growth Summit
From AIM ImmunoTech Inc.
Via GlobeNewswire
AIM ImmunoTech Secures Patent in Japan Through 2039 for Novel Cancer Therapy Combining Ampligen® (Rintatolimod) with Checkpoint Inhibitors
From AIM ImmunoTech Inc.
Via GlobeNewswire
AIM ImmunoTech Announces Publication of Journal Article On the Positive Effect of Ampligen and Interferon-Alpha on Tumor Growth
From AIM ImmunoTech Inc.
Via GlobeNewswire
AIM ImmunoTech Highlights Growing Body of Compelling Data of Ampligen for the Treatment of Pancreatic Cancer at Conference in Poland
From AIM ImmunoTech Inc.
Via GlobeNewswire
AIM ImmunoTech Announces Release of the Next CEO Corner Segment
From AIM ImmunoTech Inc.
Via GlobeNewswire
AIM ImmunoTech Reports Second Quarter 2025 Financial Results and Provides Corporate Update
From AIM ImmunoTech Inc.
Via GlobeNewswire
AIM ImmunoTech to Present at the Webull Financial Corporate Connect Webinar Series: Biotech/MedTech
From AIM ImmunoTech Inc.
Via GlobeNewswire
AIM ImmunoTech’s Oncology Drug Ampligen to Be Featured in Key Presentations and Abstract at the International 5th Annual Marie Skłodowska-Curie Symposium on Cancer Research and Care (MSCI MSCS-2025)
From AIM ImmunoTech Inc.
Via GlobeNewswire
AIM ImmunoTech Builds Positive Momentum and Reiterates Focus on Driving Ampligen® Clinical Development Toward Pancreatic Cancer Approval
From AIM ImmunoTech Inc.
Via GlobeNewswire
AIM ImmunoTech Announces Closing of $8.0 Million Public Offering
From AIM ImmunoTech Inc.
Via GlobeNewswire
AIM ImmunoTech Announces Pricing of $8.0 Million Public Offering
From AIM ImmunoTech Inc.
Via GlobeNewswire
AIM ImmunoTech Reports Positive Mid-year Safety and Efficacy Data from Phase 2 Study Evaluating Ampligen® (rintatolimod) in Combination with AstraZeneca’s Imfinzi® (durvalumab) for the Treatment of Pancreatic Cancer
From AIM ImmunoTech Inc.
Via GlobeNewswire
AIM ImmunoTech Announces Recent Presentation on the Potential of Private-Public Partnerships for the Development of Oncology Therapies
From AIM ImmunoTech Inc.
Via GlobeNewswire
Tickers AIMI
AIM ImmunoTech Announces NYSE American Notice of Noncompliance With Minimum Stockholders’ Equity Requirements
From AIM ImmunoTech Inc.
Via GlobeNewswire
Tickers AIMI
AIM ImmunoTech Resumes Trading on NYSE American
From AIM ImmunoTech Inc.
Via GlobeNewswire
Tickers AIMI
AIM ImmunoTech Granted U.S. Patent Covering Methods of Manufacturing Therapeutic dsRNA, Including Ampligen®
From AIM ImmunoTech Inc.
Via GlobeNewswire
Tickers AIMI
AIM ImmunoTech Announces NYSE American Removal of Trading Suspension
From AIM ImmunoTech Inc.
Via GlobeNewswire
Tickers AIMI
AIM ImmunoTech Announces 1-for-100 Reverse Stock Split
From AIM ImmunoTech Inc.
Via GlobeNewswire
Tickers AIMI
AIM ImmunoTech Announces the Presentation of Ampligen Oncology Data at the Recent Annual Meeting of the American Association of Immunologists
From AIM ImmunoTech Inc.
Via GlobeNewswire
Tickers AIMI
AIM ImmunoTech Announces Trading Under the Ticker AIMI on the Pink Open Market
From AIM ImmunoTech Inc.
Via GlobeNewswire
Tickers AIMI
AIM ImmunoTech Announces NYSE American Notice of Delisting and Appeal
From AIM ImmunoTech Inc.
Via GlobeNewswire
AIM ImmunoTech Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update
From AIM ImmunoTech Inc.
Via GlobeNewswire
AIM ImmunoTech Inc. Participates in the Virtual Investor “Top 5 for ‘25” On-Demand Conference
From AIM ImmunoTech Inc.
Via GlobeNewswire
AIM announces Paul Goepfert, MD, as the principal investigator for the planned clinical study of Ampligen and FluMist as a vaccine for avian influenza
From AIM ImmunoTech Inc.
Via GlobeNewswire
AIM ImmunoTech Announces NYSE American Acceptance of Plan to Regain Listing Compliance
From AIM ImmunoTech Inc.
Via GlobeNewswire
AIM ImmunoTech Appoints David Chemerow to Board of Directors as an Independent Director
From AIM ImmunoTech Inc.
Via GlobeNewswire
AIM Doses First New Subject in Phase 2 Study of Ampligen and Imfinzi as a Potential Combination Therapy for Late-Stage Pancreatic Cancer
From AIM ImmunoTech Inc.
Via GlobeNewswire
AIM ImmunoTech Releases Virtual Investor “What This Means Segment”
From AIM ImmunoTech Inc.
Via GlobeNewswire
AIM ImmunoTech announces that it will not proceed with an offering pursuant to its Registration Statement on Form S-1 until after it files its Annual Report on Form 10-K for the fiscal year ended December 31, 2024
From AIM ImmunoTech Inc.
Via GlobeNewswire
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.